2 weeks Ago By ABMN Staff
IO Biotech, Inc. ( NASDAQ:IOBT – Get Free Report ) was the target of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 122,100 shares, an increase of 136.
2% from the August 31st total of 51,700 shares. Approximately 0.3% of the company’s stock are sold short.
Based on an average trading volume of 437,700 shares, the days-to-cover ratio is currently 0.3 days. IO Biotech Price Performance IOBT opened at $1.
06 on Friday. The business has a 50 day simple moving average of $1.26 and a 200-day simple moving average of $1.
36. The stock has a market capitalization of $69.83 million, a P/E ratio of -0.
57 and a beta of 0.50. IO Biotech has a 12 month low of $0.
73 and a 12 month high of $2.10. IO Biotech ( NASDAQ:IOBT – Get Free Report ) last issued its quarterly earnings data on Tuesday, August 13th.
The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.
04. Research analysts anticipate that IO Biotech will post -1.18 EPS for the current year.
Insider Activity Hedge Funds Weigh In On IO Biotech Several hedge funds and other institutional investors have recently bought and sold shares of IOBT. XTX Topco Ltd increased its position in IO Biotech by 67.4% during the second quarter.
XTX Topco Ltd now owns 26,555 shares of the company’s stock worth $31,000 after buying an additional 10,688 shares in the last quarter. Renaissance Technologies LLC increased its position in IO Biotech by 8.1% during the second quarter.
Renaissance Technologies LLC now owns 180,800 shares of the company’s stock worth $212,000 after buying an additional 13,600 shares in the last quarter. Finally, PFM Health Sciences LP increased its position in IO Biotech by 73.0% during the fourth quarter.
PFM Health Sciences LP now owns 2,341,107 shares of the company’s stock worth $4,401,000 after buying an additional 987,654 shares in the last quarter. 54.76% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades IOBT has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of IO Biotech in a research note on Monday, September 16th.
Morgan Stanley lifted their target price on IO Biotech from $4.00 to $6.00 and gave the company an “overweight” rating in a research note on Monday, September 16th.
Finally, Piper Sandler reiterated an “overweight” rating and issued a $10.00 target price on shares of IO Biotech in a research note on Tuesday, September 3rd. Read Our Latest Stock Analysis on IOBT IO Biotech Company Profile ( Get Free Report ) IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform.
The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. Featured Stories Receive News & Ratings for IO Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IO Biotech and related companies with MarketBeat.com's FREE daily email newsletter .
.
